India is rapidly emerging as a premier global destination for multinational pharmaceutical companies to conduct clinical trials. This marks a significant shift in the industry landscape, driven by India's simplified, accessible, and expedited clinical trial processes. Over the past decade, India has experienced substantial growth of 15-18% in Phase 2...
Boehringer Ingelheim Launches Parasite Protection Products in India
Boehringer Ingelheim, a global leader in animal health, has launched NexGard SPECTRA® (afoxolaner and milbemycin oxime) in India after approval from the Central Drugs Standard Control Organisation. This represents an expansion of their successful NexGard® product line for dogs aged two months and above, weighing at least one pound. NexGard...
India’s Lupin Acquires German Diabetes Drug Rights
Mumbai-based Lupin Ltd acquired brands Ondero and Ondero-Met from drug maker Boehringer Ingelheim International GmbH, Germany. This also includes the acquisition of trademark rights associated with these brands. According to Lupin, an estimated 77 million people above the age of 18 years in India have Type-2 Diabetes, while nearly 25...